Quick access:

Ceva reorganizes its shareholding structure, welcoming new long-term partners alongside existing investors

04/02/2020

Twist Bioscience Selected as DNA Synthesis Provider for DNA Data Storage Project Under Intelligence Advanced Research Projects Activity (IARPA) Molecular Information Storage (MIST) Program

15/01/2020

Twist Bioscience Promotes Patrick Weiss to Chief Operating Officer

13/01/2020

Twist Bioscience also announces the appointment of Bill Banyai, Ph.D., as Senior Vice President of Advanced Development and General Manager of Data Storage.

MERIEUX EQUITY PARTNERS SUCCESSFULLY COMPLETES THE FUNDRAISING OF MERIEUX PARTICIPATIONS 3

08/01/2020

Mérieux Equity Partners announces the closing of the fundraising for Mérieux Participations 3, new investment fund dedicated to Growth Capital and Buy-Out within the Healthcare and Nutrition sectors, oversubscribed at € 377 million.

Genome editors begin lining up for Inscripta’s Onyx Digital Genome Engineering Platform

07/01/2020

XERIS PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM THE IN-CLINIC STAGE OF A PHASE 2 STUDY OF ITS DEVELOPMENTAL RTU GLUCAGON

06/01/2020

Results show that a mini dose of Ready-To-Use (RTU) Glucagon was adequate to maintain normal blood glucose levels in patients at risk of hypoglycemia (adults with Type 1 diabetes mellitus) during and after prolonged, moderate-to-intense aerobic exercise.

Protéus by Seqens launches SEQENZYM®, Enzyme Kits selected among an extensive library of Extremophile Strains for Fast Early Screening of Biocatalysts

12/12/2019

The easy-to-use enzyme kits can accelerate screening of enzymes for molecules synthesis transformations by facilitating rapid assessment.

Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2019 Financial Results

11/12/2019

Fiscal 2019 Revenues Increase 114% over Fiscal 2018 to $54.4M. Continued Strength in Synthetic Biology and NGS Businesses. Expect FY 2020 Revenues of $80M to $84M.

Twist Bioscience and Pandion Therapeutics Expand Antibody Optimization Collaboration

11/12/2019

Pandion is developing modular biologics and antibodies for autoimmune regulation that are designed to achieve lasting therapeutic outcomes for patients with autoimmune and inflammatory diseases.